Amylyx Pharmaceuticals: Advancing Therapies for Neurodegenerative and Endocrine Diseases
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) is a clinical-stage biopharmaceutical company dedicated to developing treatment options for patients with high unmet medical needs. Based in Cambridge, Massachusetts, the company focuses its research on neurodegenerative diseases and endocrine conditions, utilizing a pipeline of investigational therapies grounded in mechanistic rationale and preclinical data.
Key Takeaways: Amylyx Pipeline and Status
- Focus Areas: Neurodegenerative diseases and endocrine conditions.
- Key Candidate: Avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia.
- Legacy Product: AMX0035, previously approved as Relyvrio and Albrioza, was withdrawn from the North American market in April 2024.
- Current Research: Ongoing trials for Wolfram syndrome, progressive supranuclear palsy, and amyotrophic lateral sclerosis (ALS).
Current Clinical Pipeline and Therapeutic Focus
Amylyx is currently advancing several candidates designed to address rare and serious conditions. The company’s approach involves matching specific investigational therapies with diseases where they can have the most significant impact.
Endocrine Conditions: Avexitide
One of the company’s primary focuses is Avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. This therapy is currently in a phase 3 clinical trial to treat post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism. The company is also developing a long-acting version of the GLP-1 receptor antagonist for PBH and other rare diseases.
Neurodegenerative Disease Research
Amylyx continues to explore treatments for various neurodegenerative disorders:
- AMX0035: While withdrawn from the commercial market, this oral combination of sodium phenylbutyrate and taurursodiol is being studied in a phase 2 clinical trial for Wolfram syndrome and a phase 2b/3 clinical trial for progressive supranuclear palsy.
- AMX0114: This candidate is currently in a phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS).
The History and Evolution of Amylyx
Founded in 2013 by Joshua Cohen and Justin Klee while they were undergraduate students at Brown University, Amylyx began with a hypothesis that combining taurursodiol and sodium phenylbutyrate could safeguard neurons by preventing mitochondrial and endoplasmic reticulum dysfunction. The founders were advised by Rudolph E. Tanzi, who served as the founding chair of the scientific research board.
The company’s early development was supported by a $2.2 million grant from the ALS Association, funded by the Ice Bucket Challenge. Amylyx went public on the Nasdaq on January 7, 2022, under the ticker AMLX.
The Transition of AMX0035 (Relyvrio/Albrioza)
Amylyx gained significant attention with AMX0035, which was approved as Albrioza in Canada (June 2022) and Relyvrio in the United States (September 2022) for the treatment of ALS. However, following a disappointing Phase 3 trial that failed to show significant differences compared to a placebo, Amylyx announced on April 4, 2024, that it would withdraw the drug from the North American market.
Frequently Asked Questions
What is Amylyx Pharmaceuticals currently developing?
Amylyx is currently focusing on Avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism, as well as various trials for Wolfram syndrome, progressive supranuclear palsy, and ALS.
Why was Relyvrio withdrawn from the market?
Relyvrio (AMX0035) was withdrawn in April 2024 after a Phase 3 trial failed to produce significant differences versus a placebo.
Where is Amylyx Pharmaceuticals located?
The company is headquartered in Cambridge, Massachusetts.
Related reading